Special Issue "Drug Abuse Targets"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 March 2011)

Special Issue Editor

Guest Editor
Dr. Juan J. Canales
Behavioural Neuroscience, Department of Psychology, The University of Canterbury, PB 8140, Christchurch, New Zealand
Website: http://www.psyc.canterbury.ac.nz/people/canales.shtml
E-Mail: juan.canales@canterbury.ac.nz
Interests: neuroscience; neuropsychopharmacology; drug addiction; adult neurogenesis; hippocampus; memory

Special Issue Information

Dear Colleagues,

The development of more efficacious pharmacological interventions in drug addiction remains a major challenge. The pharmacological treatment of drug addiction is intended to help patients stop compulsive drug seeking and taking, ameliorate the symptoms of drug withdrawal and reduce the likelihood of relapse. Recent advances into the neurobiology and neuropharmacology of drug addiction have led to the identification of new targets and molecules that are currently under investigation as potential leads for developing specific therapeutics, including vaccines, novel monoamine transport inhibitors, dopamine agonists, cannabinoids, and compounds acting at trace amine associated receptors. This special issue is devoted to reviewing the present state of the science in neuropharmacology and medication development for drug addiction, and to identifying promising areas for future research.

Dr. Juan J. Canales
Guest Editor

Keywords

  • drug abuse and addiction
  • neurotoxicity
  • neuropsychopharmacology
  • animal models
  • monoamines
  • monoamine transporters
  • dopamine receptors

Published Papers (9 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-9
p. 1315-1327
by , , ,  and
Pharmaceuticals 2011, 4(10), 1315-1327; doi:10.3390/ph4101315
Received: 8 September 2011; Accepted: 20 September 2011 / Published: 13 October 2011
Show/Hide Abstract | PDF Full-text (300 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 1101-1136
by , ,  and
Pharmaceuticals 2011, 4(8), 1101-1136; doi:10.3390/ph4081101
Received: 7 June 2011; in revised form: 18 July 2011 / Accepted: 28 July 2011 / Published: 10 August 2011
Show/Hide Abstract | Cited by 1 | PDF Full-text (411 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 992-1018
by  and
Pharmaceuticals 2011, 4(7), 992-1018; doi:10.3390/ph4070992
Received: 22 April 2011; in revised form: 15 June 2011 / Accepted: 4 July 2011 / Published: 5 July 2011
Show/Hide Abstract | Cited by 1 | PDF Full-text (401 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 976-991
by  and
Pharmaceuticals 2011, 4(7), 976-991; doi:10.3390/ph4070976
Received: 19 April 2011; in revised form: 15 June 2011 / Accepted: 23 June 2011 / Published: 30 June 2011
Show/Hide Abstract | Cited by 4 | PDF Full-text (156 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 880-914
by , , , , ,  and
Pharmaceuticals 2011, 4(6), 880-914; doi:10.3390/ph4060880
Received: 16 May 2011; in revised form: 11 June 2011 / Accepted: 13 June 2011 / Published: 17 June 2011
Show/Hide Abstract | Cited by 9 | PDF Full-text (502 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 915-932
by  and
Pharmaceuticals 2011, 4(6), 915-932; doi:10.3390/ph4060915
Received: 2 April 2011; in revised form: 3 June 2011 / Accepted: 10 June 2011 / Published: 17 June 2011
Show/Hide Abstract | PDF Full-text (95 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 822-847
by , ,  and
Pharmaceuticals 2011, 4(6), 822-847; doi:10.3390/ph4060822
Received: 7 April 2011; in revised form: 3 June 2011 / Accepted: 7 June 2011 / Published: 15 June 2011
Show/Hide Abstract | Cited by 2 | PDF Full-text (658 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 804-821
by ,  and
Pharmaceuticals 2011, 4(6), 804-821; doi:10.3390/ph4060804
Received: 2 May 2011; in revised form: 8 June 2011 / Accepted: 8 June 2011 / Published: 14 June 2011
Show/Hide Abstract | PDF Full-text (137 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
p. 741-757
by , , , , ,  and
Pharmaceuticals 2011, 4(5), 741-757; doi:10.3390/ph4050741
Received: 15 March 2011; in revised form: 3 May 2011 / Accepted: 13 May 2011 / Published: 17 May 2011
Show/Hide Abstract | Cited by 3 | PDF Full-text (161 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Drug Abuse Targets)
Select/unselect all
Displaying article 1-9
Select articles Export citation of selected articles as:

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert